Definium Therapeutics, Inc. (DFTX) Insider Trading

Over the last 3 months, DFTX insiders made 0 open-market buys and 3 sales, a net sale of -$797K (SEC Form 4). Over the last 6 months, 2 institutions increased and 4 reduced their position (13F).

Insider Activity

Sentiment
0/100
Buys (3m)
0
Sells (3m)
3
Net (3m)
-$797.0K
Context3-month price +40.1%Institutions accumulating (13F)
DateInsiderTypeSharesPrice
Mar 26, 2026Karlin Danielofficer: Chief Medical OfficerSell8,018$18.47
Mar 26, 2026Sullivan Markofficer: Chief Legal OfficerSell10,702$18.47
Mar 26, 2026Barrow Robertdirector, officer: Chief Executive OfficerSell24,431$18.47

Source: DFTX SEC Form 4 filings, latest Mar 26, 2026. For informational purposes only — not investment advice.

Institutional activity (13F)

How institutions changed their DFTX positions over the last 6 months (SEC Form 13F).

Increased
2
New positions
243
Reduced
4
Sold out
1
Largest moves
InstitutionActionSharesFiled
BLACKROCK, INC.New Position8.5MMay 13, 2026
DRIEHAUS CAPITAL MANAGEMENT LLCReduced5.9MMay 15, 2026
AVORO CAPITAL ADVISORS LLCNew Position5.0MMay 15, 2026
JANUS HENDERSON GROUP PLCNew Position3.6MMay 18, 2026
DEEP TRACK CAPITAL, LPNew Position3.0MMay 15, 2026
GEODE CAPITAL MANAGEMENT, LLCNew Position2.5MMay 15, 2026
STATE STREET CORPNew Position2.5MMay 15, 2026
OCTAGON CAPITAL ADVISORS LPNew Position2.4MMay 15, 2026
COMMODORE CAPITAL LPNew Position2.0MMay 15, 2026
FMR LLCNew Position1.8MMay 15, 2026
Trails Edge Capital Partners, LPNew Position1.7MMay 15, 2026
GOLDMAN SACHS GROUP INCNew Position1.7MMay 15, 2026
ARROWMARK COLORADO HOLDINGS LLCNew Position1.6MMay 15, 2026
CITADEL ADVISORS LLCNew Position1.3MMay 15, 2026
WELLINGTON MANAGEMENT GROUP LLPNew Position1.3MMay 15, 2026

Source: SEC Form 13F filings. For informational purposes only — not investment advice.